Danish startup that specialises in gut microbiome health, Bactolife has raised $5 million in funding from The Bill & Melinda Gates Foundation. The new cash in its wallet will allow the company to speed up the development of binding proteins, a biologic solution to reduce the risk of gut infections in humans and animals.
Globally, there are more than 1.6 billion cases of diarrheal diseases annually, which at best means stomach upsets. But at worst, they can lead to life-threatening illnesses. According to the platform, 760,000 children die annually from gut infections. Currently, most infections are treated with antibiotics that are either very expensive or contribute to the spread of antibiotic-resistant bacteria.
Founded in 2017, the Copenhagen-based company aims to boost gut health by developing binding proteins that can reduce the risk of developing gut infections at an affordable price. Bactolife is using its proprietary binding protein technology to develop biological solutions to strengthen the gut microbiome and help solve the challenge of antimicrobial resistance development and the general burden of infectious diseases.
Mads Laustsen, CEO at Bactolife said: “The funding will allow us to reach our end customers faster and with affordable products potentially impacting millions of people’s lives worldwide.”
Sebastian Søderberg, deputy CEO at Bactolife said: “The funding is a strong validation of Bactolife’s potential to improve human and animal health worldwide and make these products accessible in developed and developing countries.”